Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 18:12:929444.
doi: 10.3389/fonc.2022.929444. eCollection 2022.

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer

Matthew Alberto  1 , Arthur Yim  1 , Nathan Papa  2 , Shankar Siva  3 , Joseph Ischia  1 , Karim Touijer  4 , James A Eastham  4 , Damien Bolton  1 , Marlon Perera  1   4
Affiliations
Review

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer

Matthew Alberto et al. Front Oncol. .

Abstract

Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT.

Keywords: PSMA PET; metastastases directed therapy; metastatic disease; oligometastatic; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. . Screening and prostate-cancer mortality in a randomized European study. New Engl J Med (2009) 360(13):1320–8. doi: 10.1056/NEJMoa0810084 - DOI - PubMed
    1. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. . EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol (2017) 71(4):618–29. doi: 10.1016/j.eururo.2016.08.003 - DOI - PubMed
    1. Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, et al. . Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: Results from a multi-institutional study of 1100 patients. Eur Urol. (2015) 68(3):497–505. doi: 10.1016/j.eururo.2015.06.020 - DOI - PubMed
    1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. . Characterisation and classification of oligometastatic disease: A European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol (2020) 21(1):e18–28. doi: 10.1016/S1470-2045(19)30718-1 - DOI - PubMed